Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bird Flu
The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
November 9th, 2007
The Quigley Corporation (NASDAQ:QGLY) reported net sales of $11.8 million, for the third quarter ended September 30, 2007, compared to $11.5 million reported for the same period in 2006. For the nine-months ended September 30, 2007, net sales were $25.9 million compared to $27.9 million reported for the same period in 2006. The third quarter and first nine months of 2007 reflect a net sales increase for the Company's Cold Remedy segment of $1.0 million and $1.6 million, respectively, as compared to the same periods of 2006. These increases include a price increase and inaugural sales of two new COLD-EEZE(R) branded line extensions that commenced on July 2, 2007. The...
Source: Biotech Law Weekly (2007-11-09)
|
